Clinical trials: Zoster; Herpes
Herpes Zoster, Herpes Zoster Vaccine
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine…
- Trial name
- NCT02723773
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 161 sites in United States, Australia and 16 more
- Volunteers
- 7,539 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT01954251
- Testing
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of valaciclovir in pediatric patients with chickenpox
- Trial name
- NCT01390857
- Testing
- Valaciclovir
- Volunteers
- 379 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster Keratitis
Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis
The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis.
- Trial name
- NCT02382588
- Testing
- gancyclovir gel, Hypromellose gel
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)
This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic…
- Trial name
- NCT01527383
- Testing
- V212
- Volunteers
- 354 people
- Sponsor
- Merck Sharp & Dohme LLC
Virus Diseases, Herpes Zoster
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders.
- Trial name
- 168 (NCT00921934)
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Herpes Zoster
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older.
- Trial name
- NCT01610414
- Testing
- Herpes Zoster vaccine GSK1437173A
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 1,877 people
- Sponsor
- GlaxoSmithKline
Healthy
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.
- Trial name
- NCT00092417
- Testing
- Comparator: Varicella Zoster Virus Vaccine
- Volunteers
- 695 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Herpes Zoster Vaccine
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine.
- Trial name
- NCT02075515
- Testing
- Herpes Zoster vaccine (GSK 1437173A)
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 651 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem…
- Trial name
- NCT00920218
- Testing
- Herpes Zoster Vaccine 1437173A
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Inflammatory Arthritis
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor…
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis
- Trial name
- NCT02538341
- Testing
- Herpes Zoster (HZ) Vaccine
- Where
- 34 sites in United States
- Volunteers
- 617 people
- Sponsor
- University of Alabama at Birmingham
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Varicella
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety.
- Trial name
- NCT00568334
- Testing
- Varilrix (inactivated varicella vaccine)
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles, Mumps
ProQuad Dose Selection Study (V221-011)(COMPLETED)
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00986232
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV
- Volunteers
- 1,551 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile to that of…
- Trial name
- NCT00130793
- Testing
- Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation, Comparator: zoster vaccine live (Oka/Merck) frozen formulation
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC